Should I buy or sell Corvus Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRVS shares. View CRVS analyst ratings or view top-rated stocks .

What is Corvus Pharmaceuticals' stock price target for 2024?

3 Wall Street analysts have issued 1 year price targets for Corvus Pharmaceuticals' stock. Their CRVS share price targets range from $3.50 to $12.00. On average, they predict the company's stock price to reach $6.63 in the next twelve months. This suggests a possible upside of 387.1% from the stock's current price. View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts .

How have CRVS shares performed in 2024?

Corvus Pharmaceuticals' stock was trading at $1.76 at the beginning of 2024. Since then, CRVS stock has decreased by 22.7% and is now trading at $1.36. View the best growth stocks for 2024 here .

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,400,000 shares, a decline of 6.0% from the March 15th total of 1,490,000 shares. Based on an average daily volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days. Currently, 3.8% of the company's shares are sold short. View Corvus Pharmaceuticals' Short Interest .

When is Corvus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our CRVS earnings forecast .

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Tuesday, March, 19th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14).

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com . Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Dynavax Technologies (DVAX) , Vaxart (VXRT) , Zosano Pharma (ZSAN) , SCYNEXIS (SCYX) , Miragen Therapeutics (MGEN) , Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO) .

When did Corvus Pharmaceuticals IPO?

Corvus Pharmaceuticals (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free CRVS Stock Alerts

$1.36

-0.11 (-7.48%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.36
▼
$1.51
50-Day Range: $1.47
▼
$2.36
52-Week Range: $0.98
▼
$4.19

Volume: 112,505 shs
Average Volume: 200,532 shs
Market Capitalization: $66.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.63

Get Corvus Pharmaceuticals alerts:

Corvus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 387.1% Upside
$6.63 Price Target
Short Interest: Healthy
3.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.84
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.47) to ($0.69) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.74 out of 5 stars

Medical Sector

404th out of 913 stocks

Pharmaceutical Preparations Industry

182nd out of 421 stocks

3.3

Analyst's Opinion

Consensus Rating
Corvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Corvus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.79% of the float of Corvus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Corvus Pharmaceuticals has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Corvus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corvus Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRVS.

3.8

News and Social Media Coverage

News Sentiment
Corvus Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
34 people have searched for CRVS on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.
MarketBeat Follows
2 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.47) to ($0.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corvus Pharmaceuticals is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corvus Pharmaceuticals is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corvus Pharmaceuticals has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CRVS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRVS Stock News Headlines

April 18, 2024 | americanbankingnews.com

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update

April 17, 2024 | finance.yahoo.com

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 13, 2024 | americanbankingnews.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Below Fifty Day Moving Average of $2.01

April 9, 2024 | globenewswire.com

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

March 21, 2024 | seekingalpha.com

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript

March 21, 2024 | finance.yahoo.com

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript

March 21, 2024 | finanznachrichten.de

Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 20, 2024 | finance.yahoo.com

Q4 2023 Corvus Pharmaceuticals Inc Earnings Call

March 19, 2024 | stockhouse.com

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 19, 2024 | globenewswire.com

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 16, 2024 | finance.yahoo.com

CRVS Apr 2024 4.000 put

March 13, 2024 | globenewswire.com

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

March 9, 2024 | finance.yahoo.com

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully

February 17, 2024 | finance.yahoo.com

CRVS Mar 2024 3.000 put

February 12, 2024 | msn.com

Corvus Edges up on Disclosing Data

February 12, 2024 | finance.yahoo.com

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

February 8, 2024 | marketwatch.com

Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation

February 8, 2024 | msn.com

Corvus lymphoma drug gets FDA orphan drug status

February 8, 2024 | finance.yahoo.com

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

February 6, 2024 | finance.yahoo.com

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

January 23, 2024 | finance.yahoo.com

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

January 5, 2024 | finance.yahoo.com

Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week

December 13, 2023 | markets.businessinsider.com

Maintaining Hold Rating on Corvus Pharmaceuticals Amid Steady but Unspectacular Clinical Progress

December 7, 2023 | msn.com

Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?

November 21, 2023 | finance.yahoo.com

Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?

See More Headlines

Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CRVS
CUSIP: N/A
CIK: 1626971
Web: www.corvuspharma.com
Phone: (650) 900-4520
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.63
High Stock Price Target: $12.00
Low Stock Price Target: $3.50
Potential Upside/Downside: +387.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -59.63%
Return on Assets: -50.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.07
Quick Ratio: 4.07

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.79 per share
Price / Book: 1.72

Miscellaneous

Outstanding Shares: 49,040,000
Free Float: 33,690,000
Market Cap: $66.69 million
Optionable: Optionable
Beta: 1.02

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Richard A. Miller M.D. (Age 73)
Co-Founder, President, CEO & Chairman of the Board
Comp: $306k
Dr. Peter A. Thompson FACP (Age 64)
M.D., Co-Founder & Independent Director
Comp: $47k
Mr. Leiv Lea (Age 70)
Chief Financial Officer
Comp: $388.73k
Dr. William Benton Jones Ph.D. (Age 58)
Senior Vice President of Pharmaceutical Development
Comp: $346.42k
Dr. James T. Rosenbaum M.D.
Senior Vice President of Research
Mr. Jeffrey S. Arcara
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRVS shares.
View CRVS analyst ratings or view top-rated stocks.
What is Corvus Pharmaceuticals' stock price target for 2024?: 3 Wall Street analysts have issued 1 year price targets for Corvus Pharmaceuticals' stock. Their CRVS share price targets range from $3.50 to $12.00. On average, they predict the company's stock price to reach $6.63 in the next twelve months. This suggests a possible upside of 387.1% from the stock's current price.
View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts.
How have CRVS shares performed in 2024?: Corvus Pharmaceuticals' stock was trading at $1.76 at the beginning of 2024. Since then, CRVS stock has decreased by 22.7% and is now trading at $1.36.
View the best growth stocks for 2024 here.
Are investors shorting Corvus Pharmaceuticals?: Corvus Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,400,000 shares, a decline of 6.0% from the March 15th total of 1,490,000 shares. Based on an average daily volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days. Currently, 3.8% of the company's shares are sold short.
View Corvus Pharmaceuticals' Short Interest.
When is Corvus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our CRVS earnings forecast.
How were Corvus Pharmaceuticals' earnings last quarter?: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Tuesday, March, 19th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14).

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?: 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.
What other stocks do shareholders of Corvus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).
When did Corvus Pharmaceuticals IPO?: Corvus Pharmaceuticals (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
How do I buy shares of Corvus Pharmaceuticals?: Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRVS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Corvus Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

CRVS Stock Price History

CRVS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CRVS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™